Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg is a Product of the Generic Duloxetine Hydrochloride

What Is Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg Indications and Uses?

Xinolax DR is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for- Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Diabetic Peripheral Neuropathic Pain (DPNP) Fibromyalgia and Chronic Musculoskeletal Pain.

Pharmacology (Source, Chemical and Physical Composition) Of Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg

Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg (Duloxetine Hydrochloride) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.

Dosage And Administration of Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg

Major Depressive Disorder (MDD)- Starting Dose : 40 mg/day to 60 mg/day Target Dose : Acute: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance: 60 mg/day Maximum Dose : 120 mg/day Generalized Anxiety Disorder (GAD)- Starting Dose : 60 mg/day Target Dose : 60 mg/day (once daily) Maximum Dose : 120 mg/day Diabetic Peripheral Neuropathic Pain (DPNP)- Starting Dose : 60 mg/day Target Dose : 60 mg/day (once daily) Maximum Dose : 60 mg/day Fibromyalgia- Starting Dose : 30 mg/day Target Dose : 60 mg/day (once daily) Maximum Dose : 60 mg/day Chronic Musculoskeletal Pain- Starting Dose : 30 mg/day Target Dose : 60 mg/day (once daily) Maximum Dose : 60 mg/day Some patients may benefit from starting at 30 mg once daily. There is no evidence that doses greater than 60 mg/day confers an additional benefit, while some adverse reactions were observed to be dose-dependent. A gradual dose reduction is recommended to avoid discontinuation symptoms.

Drug Interactions of Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg

Both CYP1A2 and CYP2D6 isozymes are responsible for Xinolax DR metabolism. When Xinolax DR was co-administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t of Xinolax DR was increased. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in Xinolax DR metabolism, concomitant use of Xinolax DR with potent inhibitors of CYP2D6 may result in higher concentrations of Xinolax DR.

Side Effects of Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg

The most commonly observed adverse events in Xinolax DR treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Xinolax DR-treated and placebo-treated patients.

Precautions And Warnings for Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Xinolax DR and NSAIDs, aspirin, or other drugs that affect coagulation. Xinolax DR should be used cautiously in patients with a history of mania. Xinolax DR should be prescribed with care in patients with a history of a seizure disorder.

Use During Pregnancy and Lactation

Pregnancy : Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Xinolax DR Capsule (Delayed Release) DR Capsule 30 mg (Duloxetine Hydrochloride) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery : The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus. Lactation : It is unknown whether or not Duloxetine and/or it's metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended

Therapeutic Class

Serotonin-norepinephrine reuptake inhibitor (SNRI)

Storage Conditions of It

Do not store above 30°C. Keep away from light and out of the reach of children. Pack Image: Xinolax DR 30 mg DR Capsule Thanks for using MedEx! How would you rate your experience so far?